Sage Therapeutics (NASDAQ: SAGE)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Sage Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sage Therapeutics Company Info
Sage Therapeutics, Inc.
News & Analysis
Investors can see the finish line for the company's second marketed therapy.
The late-stage trial results for the company's major depressive disorder drug aren't impressing investors today.
Sage has been struggling for some time to bring its flagship antidepressant to the market.
The neuroscience-focused biotech company didn't give investors the result they wanted.
Long-awaited clinical trial results weren't as successful as hoped.
Can this brain health-focused biotech continue to rise, or will it fade -- again?
Each company has suffered a clinical failure recently, but this team-up could do good things for both.
With its recent clinical trial stumble and falling revenues for its only approved drug on the market, Sage may be in trouble.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 04/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
SAGE earnings call for the period ending September 30, 2021.
SAGE earnings call for the period ending June 30, 2021.
SAGE earnings call for the period ending March 31, 2021.
SAGE earnings call for the period ending September 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.